Important Safety Information

Unique Treatment, Proven Safety

  • OLUX-E® Foam is safe for use in patients 12 years of age or older when applied BID for 2 weeks.
  • Less than 2% of patients experienced application site reaction, and less than 2% experienced mild application site atrophy, which was reversible upon discontinuation (N=572).2
  • Less than 1% of patients withdrew due to treatment-related adverse events.2
  • Less than 1% of patients reported severe adverse events (1 application site burning and 1 application site reaction).2
  • No instances of corticosteroid withdrawal or rebound were reported in clinical trials.2

OLUX-E® Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. Treatment should be limited to 2 consecutive weeks and patients should not use greater than 50 grams per week.

OLUX-E® Foam has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Click here for additional information on HPA axis supression.

The pooled incidence of local adverse reactions in trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with OLUX-E® Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

Rebate Offer

Instantly save up to $35 off your OLUX-E® Foam prescription (even works with copay).

learn more

Patient Information Brochure

Download this helpful patient information brochure to learn more about OLUX-E® Foam and dermatoses.

download